Cover Image
市場調查報告書

心律不整:開發平台分析

Arrhythmias - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 219844
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
心律不整:開發平台分析 Arrhythmias - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 46 Pages
簡介

所謂心律不整是心跳速度或頻律障礙。在心律不整期間心臟跳動會變得非常快、非常慢、或是不規律。症狀有不安、虛弱、暈眩、失去平衡感、失神或是快要失神、發汗、呼吸困難及胸口疼痛等。治療法有抗心律不整藥及抗凝固劑等。

本報告提供全球治療心律不整所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心律不整概要

治療藥的開發

  • 心律不整開發中產品:概要
  • 心律不整開發中產品:比較分析

心律不整:各企業開發中的治療藥

心律不整:大學/研究機關研究中的治療藥

心律不整:開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

心律不整:開發中的產品一覽(各企業)

心律不整:研究中的產品一覽(大學/研究機關別)

心律不整的開發企業

  • Cynata Therapeutics Limited
  • Gilead Sciences, Inc.
  • 小野藥品工業
  • Orion Oyj
  • SciFluor Life Sciences, LLC
  • SignPath Pharma Inc

心律不整:治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • aladorian sodium
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome
  • efsevin
  • eleclazine
  • EU-8120
  • GS-967
  • KN-93
  • landiolol
  • LH-021
  • ORM-10103
  • PP-1
  • Small Molecule for Arrhythmia
  • Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia
  • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure
  • Stem Cell Therapy for Cardiovacular Diseases
  • VKII-86

心律不整:開發中產品的最新趨勢

心律不整:開發暫停的產品

心律不整:開發中止的產品

心律不整相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9605IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H2 2017, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arrhythmias - Overview
    • Arrhythmias - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Arrhythmias - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Arrhythmias - Companies Involved in Therapeutics Development
    • Cynata Therapeutics Ltd
    • Gilead Sciences Inc
    • LATITUDE Pharmaceuticals Inc
    • Ono Pharmaceutical Co Ltd
    • Orion Oyj
    • SignPath Pharma Inc
  • Arrhythmias - Drug Profiles
    • amiodarone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • efsevin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EU-8120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KN-93 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landiolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-201A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORM-10103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAM-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target FKBP1A for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPP-4040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VKII-86 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Arrhythmias - Dormant Projects
  • Arrhythmias - Discontinued Products
  • Arrhythmias - Product Development Milestones
    • Featured News & Press Releases
      • Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Arrhythmias, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Arrhythmias - Pipeline by Cynata Therapeutics Ltd, H2 2017
  • Arrhythmias - Pipeline by Gilead Sciences Inc, H2 2017
  • Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
  • Arrhythmias - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Arrhythmias - Pipeline by Orion Oyj, H2 2017
  • Arrhythmias - Pipeline by SignPath Pharma Inc, H2 2017
  • Arrhythmias - Dormant Projects, H2 2017
  • Arrhythmias - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Arrhythmias, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top